The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11939666 This looks like a big deal, not sure about the money side but WIL Research and Instem in a similar line of business I think. http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11939666 http://wilresearch.com/about-us/we-have-listening-down-science
The Group has continued to increase its share of the preclinical market and made important strategic progress including expansion of its product sets and entry into the early phase clinical market. The increase in new SaaS deals signed in the year is particularly pleasing. Our SaaS offer is compelling for clients and provides the Group with increasing long-term revenue visibility. Instem, like other pharmaceutical services companies, is beginning to see an improvement in its end markets, with the global pharmaceutical market re-focusing its efforts into early stage development work. In addition, the industry’s regulatory and fiscal pressures continue to work in Instem’s favour, driving demand for all areas of our product portfolio. With the benefit of a full year’s contribution from both the Instem Clinical and more recent Perceptive Instruments acquisitions, we look forward to 2014 with confidence. P J Reason, Chief Executive http://investors.instem.com/docs/instem-annual-report-2013.pdf
Can shift!!!
Investors in the drug development sector will hope that the AIM-listed Instem's bankers are perceptive. The drug development data company has paid £1.3m to acquire Perceptive Instruments, which follows a similar deal to buy Logo Technologies in May. Instem shares, up 50% this year, gained 2p to close at 163.5p.
Acquisition RNS The incorporation of further capabilities broadens Instem's repertoire, increases the strategic importance of Instem to its clients, and complements the Group's existing solutions. Perceptive's products support the R&D processes at the stage immediately prior to Instem's current solutions, providing opportunities to enhance workflow and data integration across multiple current and anticipated product lines. Instem believes Perceptive will benefit from the Group's global sales and marketing capability, particularly in the Americas and China where Perceptive has previously had less exposure and penetration, and where Instem has achieved a high level of traction. The launch of Cyto Study Manager in Q1 2014 is also expected to be a driver for further growth, targeting the entire Instem and Perceptive client base. Operating in closely connected market segments of the R&D continuum, Instem and Perceptive are serving related client needs, and therefore opportunities exist to cross sell product suites. Current trading in-line with expectations Instem remains on course to meet market expectations for the financial year ending 31 December 2013. The acquisition of Logos Technologies and its re-brand to Instem Clinical has been successfully completed and is performing ahead of expectations. Whilst there are continuing signs of improved confidence amongst our Provantis customers, the Group is still experiencing some deferral in perpetual licences. As usual, the outcome for 2013 will rely on the placing of certain anticipated contracts prior to the end of the year and the Group will provide a full pre-close update in January.
Agreed,I bought more, now, what to sell.........
The message about future prospects and pipeline looks especially good - looks like they are expecting a strong end to the financial year and we can look forward to steady growth in the SP
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11720104 Phil Reason, CEO of Instem plc, commented: "We are very pleased with Instem's strategic, operational and financial progress in the first half of the year. We have continued to broaden our product range, extend our geographical reach and sign top tier clients across the breadth of our expanded product set. In addition, Instem also made an important move into the early phase clinical market through the acquisition of Logos Technologies, which has already proven beneficial. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite. With a strong order intake in the first half, the Board continues to view the future prospects for the business with confidence." Instem is a robust business, with net cash and a valuable blue-chip customer base delivering high levels of recurring revenue. We believe Instem has bolstered its already strong position, and is well placed to take advantage of the structural changes in the processes of drug development that are currently taking place, which should drive further growth in global demand across our expanded product set.
Some excellent RNS's recently and this was madly undervalued at 1-1.20 - One or two more positive pieces of news and this will be back to £2+ imo
would like to see what the us will think of this wait for us markets.great contract with more coming.11 mill mcap this contract worth more than that
Have sold out and gone to AGL. Good luck all.
u state u sold at 145 how did you manage that best buy in was 145 bid 137.is it me if you did get that which i dont doubt whos your broker
Mate, read RNS at 07.00, checked out company, did not seem to be a lot of volume in previous trades to sustain a big rise IMO. Shares rose up nearly 50%, falling back to 40 % now. I am in agl, tcg, avn, ba8, gdl + cey. I research companies, read RNS' s and announcements and make my own mind up. My money, my risk. I would never advise anybody else what to do with their money. Regards
It is all about opinions mate. I only observe. Never do I advise, don't mean to annoy anyone. Regards
With this & AGL RNS today I think I will have a big smile on my face going in to March :-)
Pump + dump IMO
I think this has more legs Today...
"JOINN Laboraties China has purchased Provantis Preclinical software solution suite to automate processes within it's China based facilities. JOINN is China's largest provider of preclinical studies to the Instem client community. their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the longer term growth potential in what is already the third largest pharmaceutical market in the world".
Shares of Instem fell 2.2% at 08:40 in London.
Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending. The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months. In its update on trading for the year ending December 31st 201 Instem added that their clients' ability to contribute to current year results will only be known definitively at the year-end. As a result, Instem now intends to announce its planned trading update in early January.
The fundamentals of the business remain strong and Instem continues to: · increase its substantial annual recurring revenues; · remain solidly profitable and cash generative, with £1.84m net cash as at 30 June 2012 (£1.33m at 30 June 2011); · win the majority of new business placed in its core early development safety assessment market; and · benefit from high barriers to entry for competitors. Enhanced revenue opportunities and reduced costs resulting from the completion of the last major phase of the redevelopment of its core Provantis® product suite during 2012 are expected to contribute positively to future business performance. Overall, while the Board remains cautious regarding the timing of deal flow, it is confident in the medium to long-term prospects for the business, which remains well positioned to benefit from the trends in its end markets towards multi-site, collaborative and outsourced R&D. Notice of Results The Company expects to report interim results for the 6 months ended 30 June 2012 on 19 September 2012.